Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY

The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine/DMT, Lystergic Acid Diethylamide/LSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are: 1. Do serotonergic psychedelics cause the brain to rely on new information more than previously learned information while under the influence? What about 1 day, 5-14 days, and 4-6 weeks after use? 2. Do serotonergic psychedelics cause long-lasting side-effects in how people perceive (see, hear, feel, etc.) the world and how easily people change their beliefs? 3. How does the brain's electrical activity change after using serotonergic psychedelics? How does the balance between excitation and inhibition change while under their effect? 4. Can changes in how the brain uses information predict who will benefit from a psychedelic and who will have side effects from psychedelics? Researchers will compare with people given placebos to see what changes in brain processing are unique to serotonergic psychedelics. Participants will have the opportunity to do some combination of the following: 1. Online computer assessments consisting of games and questionnaires that probe how participants think. 2. Magnetoencephalography (MEG) or electroencephalography (EEG) with eyes closed and with repeated clicks, images, or sensations delivered. 3. A magnetic resonance imaging (MRI) scan. 4. Semi-structured qualitative interviews about their experience after taking a serotonergic psychedelic recorded via Zoom.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Participation in approved clinical protocol at Yale University involving potential administration of serotonergic psychedelics

• Absence of pre-existing psychotic symptoms

Locations
United States
Connecticut
Connecticut Mental Health Center
RECRUITING
Hamden
West Haven VA Medical Center
RECRUITING
West Haven
Contact Information
Primary
Maximillian S Greenwald, BA
maximillian.greenwald@yale.edu
4254959793
Backup
Albert R Powers, MD,PhD
albert.powers@yale.edu
2039010290
Time Frame
Start Date: 2024-12-12
Estimated Completion Date: 2028-05
Participants
Target number of participants: 200
Treatments
Serotonergic Psychedelic Arm
Group (healthy or with psychological or neurological disorder) administered serotonergic psychedelic (psilocybin, DMT, LSD, 5-MeO-DMT, Ayahuasca, etc.) regardless of administration route.
Placebo Arm
Group (healthy or with psychological or neurological disorder) administered placebo (diphenydramine, saline, niacin, etc.) regardless of administration route.
Sponsors
Leads: Yale University
Collaborators: Burroughs Wellcome, National Institutes of Health (NIH)

This content was sourced from clinicaltrials.gov